# EDGAR Filing Document

**Accession Number:** 0001833769
**File Stem:** 0001193125-26-009859
**Filing Date:** 2026-1
**Character Count:** 43653
**Document Hash:** 5b56358eedbddbd66cafe4cd38375867
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-009859.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001193125-26-009859

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 35

**CONFORMED PERIOD OF REPORT**: 20260112

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hyperfine, Inc.
- **CENTRAL INDEX KEY:** 0001833769
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39949
- **FILM NUMBER:** 26524803

**BUSINESS ADDRESS:**
- **STREET 1:** 351 NEW WHITFIELD STREET
- **CITY:** GUILFORD
- **STATE:** CT
- **ZIP:** 06437
- **BUSINESS PHONE:** 866-796-6767

**MAIL ADDRESS:**
- **STREET 1:** 351 NEW WHITFIELD STREET
- **CITY:** GUILFORD
- **STATE:** CT
- **ZIP:** 06437

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HealthCor Catalio Acquisition Corp.
- **DATE OF NAME CHANGE:** 20201124

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of The Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 12, 2026

## Hyperfine, Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39949** | **98-1569027** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **351 New Whitfield Street**<br> **Guilford, Connecticut** | **06437** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code (866) 796-6767
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Class A common stock, $0.0001 par value per share | HYPR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.**  |

---

On January 12, 2026, Hyperfine, Inc. (the "Company") issued a press release and updated its corporate presentation (the "Investor Presentation"), as described further below, each of which included information with respect to certain preliminary unaudited financial results of the Company. For the quarter ended December 31, 2025, the Company had estimated total revenue of approximately $5.3 million, for the fiscal year ended December 31, 2025, the Company had estimated total revenue of approximately $13.5 million, and the Company had estimated cash and cash equivalents of approximately $35.1 million as of December 31, 2025.

The estimated total revenue for the quarter and year ended December 31, 2025 and the estimated cash and cash equivalents as of December 31, 2025 are preliminary and may change, and are based on information available to management as of the date of this Current Report on Form 8-K (the "Report") and are subject to completion by management of the financial statements as of and for the year ended December 31, 2025. There can be no assurance that the Company's total revenue for the quarter or year ended December 31, 2025 or the cash and cash equivalents as of December 31, 2025 will not differ from these estimates and any such changes could be material. The preliminary financial data included in this Report has been prepared by and is the responsibility of the Company's management. The Company's independent registered public accounting firm has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, the Company's independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto. Complete results will be included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

The information in this Item 2.02 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosures.**  |

---

On January 12, 2026, the Company issued a press release entitled "Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results", a copy of which is attached and furnished hereto as Exhibit 99.1. In addition, on January 12, 2026, the Company updated its Investor Presentation, which management intends to use from time to time in general corporate communications, investor communications and conferences. A copy of the Investor Presentation is attached and furnished hereto as Exhibit 99.2 and is also available on the "Investor Relations" portion of the Company's website. The Investor Presentation is current as of January 12, 2026, and the Company disclaims any obligation to update the Investor Presentation after such date.

The information in this Item 7.01 and Exhibits 99.1 and 99.2 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | [Press Release of Hyperfine, Inc., dated January 12, 2026.](d949104dex991.htm) |
| 99.2 | [Investor Presentation of Hyperfine, Inc., dated January 12, 2026.](d949104dex992.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **HYPERFINE, INC.** |
| Date: January 12, 2026 | /s/ Brett Hale |
|  | Brett Hale |
|  | Chief Administrative Officer, Chief Financial Officer, Treasurer and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1** 

**Hyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results** 

*Hyperfine Delivers Quarterly Record Revenue of Approximately $5.3 Million in Q4 2025, Representing Transformative Growth of 54% Compared to Prior Quarter; Exiting 2025 with Approximately $35 Million of Cash and Cash Equivalents.* 

**Guilford, CONN. – January 12, 2026** – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop<sup>®</sup> system—today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the fourth quarter and full year ended December 31, 2025.

**Fourth Quarter 2025 Preliminary, Unaudited Financial Results** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Preliminary, unaudited revenue for the fourth quarter 2025 is expected to be approximately $5.3 million,
representing growth of 127% compared to the fourth quarter of 2024 and 54% sequentially compared to the third quarter of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Preliminary, unaudited net cash burn for the fourth quarter of 2025 excluding financings is expected to be
approximately $5.7 million<sup>1</sup>, down 30% compared to the fourth quarter of 2024 and 3% sequentially compared to the third quarter of 2025.

**Full Year 2025 Preliminary, Unaudited Financial Results** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Preliminary, unaudited revenue for the year ended December 31, 2025 is expected to be approximately
$13.5 million, representing growth of 5% compared to the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Preliminary, unaudited net cash burn for the year ended December 31, 2025 excluding financings is expected
to be approximately $29.9 million<sup>1</sup>, down 22% compared to the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Preliminary, unaudited cash and cash equivalents as of December 31, 2025 is expected to be approximately
$35.1 million.

"I am very pleased with our record fourth quarter, driven by success across all business verticals with placements in hospitals including technology upgrades, in neurology offices, and international markets," said Maria Sainz, President and CEO of Hyperfine, Inc. "We are seeing the realization of mainstream adoption of our technology following the recent launches of the next generation Swoop<sup>®</sup> System, the Optive AI<sup>TM</sup> software, and our entrance into the new neurology office market."

Hyperfine expects to provide complete fourth quarter and full year 2025 financial results and 2026 financial outlook during its fourth quarter 2025 earnings call in March 2026.

<sup>1</sup> Cash burn is calculated as change in cash and cash equivalents less net financing proceeds, which includes shares issued under the Company's "at-the-market" offering program, the Company's February 2025 registered direct offering, and the Company's October 2025 underwritten public offering. Cash and cash equivalents were $45.8 million as of September 30, 2024, $37.6 million as of December 31, 2024, $21.6 million as of September 30, 2025, and preliminary, unaudited are expected to be approximately $35.1 million as of December 31, 2025; net financing proceeds in the aggregate were less than $0.1 million for the quarter ended December 31, 2024, and preliminary, unaudited are expected to be approximately $19.3 million for the quarter ended December 31, 2025. Cash and cash equivalents were $75.2 million as of December 31, 2023, $37.6 million as of December 31, 2024, and preliminary, unaudited are expected to be approximately $35.1 million as of December 31, 2025; net financing proceeds in the aggregate were $0.8 million for the year ended December 31, 2024, and preliminary, unaudited are expected to be approximately $27.3 million for the year ended December 31, 2025. All quarterly numbers presented herein are unaudited. 

------

**About the Swoop<sup>®</sup> Portable MRI Systems** 

The Swoop<sup>®</sup> Portable MR Imaging<sup>®</sup> Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

**About Hyperfine, Inc.** 

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop<sup>®</sup> system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop<sup>®</sup> system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit <u>HyperfineMRI.com</u>.

The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc.

**Use of Non-GAAP Financial Information** 

Hyperfine, Inc. has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measure included in this press release is net cash burn. Management uses this non-GAAP financial measure, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measure does not include the impact of items that management does not consider indicative of Hyperfine, Inc.'s core operating performance. Management believes that this non-GAAP financial measure, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain financing proceeds that are not indicative of the Company's core operating results. Management uses non-GAAP measures to compare the Company's performance relative to forecasts and strategic plans and to benchmark the Company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company's operating results as reported under U.S. GAAP. Hyperfine, Inc. encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. The reconciliation between GAAP and non-GAAP net cash burn is presented above.

**Preliminary Financial Information** 

The preliminary financial information included in this press release is unaudited and is subject to completion of Hyperfine, Inc.'s quarter-end and year-end closing procedures and further financial review. Actual results may differ from these estimates as a result of the completion of quarter-end and year-end closing procedures, review adjustments and other developments that may arise between now and the time such financial information for the periods is finalized. As a result, these estimates are preliminary, may change and constitute forward-looking information and, as a result, are subject to risks and uncertainties. These preliminary estimates should not be viewed as a substitute for full financial statements prepared in accordance with United States generally accepted accounting principles, and they should not be viewed as indicative of our results for any future period. Hyperfine, Inc.'s independent registered public accountants have not audited, reviewed, compiled, or performed any procedures with respect to these estimated financial results and, accordingly, do not express an opinion or any other form of assurance with respect to these preliminary estimates.

**Forward-Looking Statements** 

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations about the Company's financial and operating results, including the Company's expected revenue, cash position, and cash burn, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance, including its financial performance, and its ability to implement its strategy, including its entrance into new markets. These forward-looking statements involve significant risks and uncertainties

------

that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the completion the Company's quarter-end and year-end closing procedures for its financial statements for the year ended December 31, 2025; the success, cost and timing of the Company's product development and commercialization activities, including the degree that the *Swoop<sup>®</sup>* system is accepted and used by healthcare professionals; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq Stock Market; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to progress on product advancements and improvements; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; anticipated National Institutes of Health funding pressures; the effect of U.S. export controls and tariffs; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

**Contacts** 

**Media Contact**

Devin Zell

Hyperfine

<u>dzell@hyperfine.io</u> 

**Investor Contact** 

Webb Campbell

Gilmartin Group LLC

<u>webb@gilmartinir.com</u> 

\# \# \#

## Exhibit 99.2

![](g949104ex99_2p1g1.jpg)

Exhibit 99.2 AI-POWERED, PORTABLE BRAIN MRI The Swoop® Portable MR Imaging System is Driving the Future of Brain Health Corporate Investor Deck – January 2026 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo is a trademark of Hyperfine, Inc. PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p2g1.jpg)

Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, including the Company's expansion plans; the benefits of the Company's products and services, including the clinical evidence supporting those benefits; the market demand and acceptance for the Company's products and services; the Company's cash runway; the Company's future performance, including its financial performance; and the Company's ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to the completion the Company's quarter-end and year-end closing procedures for its financial statements for the year ended December 31, 2025; the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the Company's ability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the inability of the Company to progress on product advancements and improvements; the ability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the ability of the Company to identify, in-license or acquire additional technology; the ability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the ability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; anticipated National Institutes of Health funding pressures; the effect of U.S. export controls and tariffs; the Company's ability to generate clinical evidence of the benefits of the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission (the "SEC"), including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. This presentation includes preliminary financial estimates for the quarter and year ended December 31, 2025, which reflect management's current views and may change as a result of management's final review of results and other factors, including significant business, economic and competitive risks and uncertainties. Such preliminary financial information is subject to the finalization and closing of the accounting books and records of the Company (which have yet to be performed). In the course of preparing and finalizing these accounting books and records, and in preparing financial statements for the year ended December 31, 2025, the preliminary estimates for the quarter and year ended December 31, 2025 will be subject to change and the Company may identify items that will require it to make adjustments to the Company's preliminary estimates described herein. Any such changes could be material. For these or other reasons, the preliminary financial estimates for the quarter and year ended December 31, 2025 may not ultimately be indicative of the Company's results for such period and actual results may differ materially from those described above. No independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to these preliminary results, nor have they expressed any opinion or any other form of assurance on these preliminary results. These unaudited preliminary financial estimates are presented for informational purposes only and do not purport to represent the Company's financial condition or results of operations for any future date or period. As a result, caution should be exercised in relying on these estimates and no inferences should be drawn from these estimates regarding financial or operating data not provided. The Company has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measure included in this presentation is net cash burn. Management uses this non-GAAP financial measure, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measure does not include the impact of items that management does not consider indicative of the Company's core operating performance. Management believes that this non-GAAP financial measure, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain financing proceeds that are not indicative of the Company's core operating results. Management uses non-GAAP measures to compare the Company's performance relative to forecasts and strategic plans and to benchmark the Company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company's operating results as reported under U.S. GAAP. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. The reconciliation between GAAP and non-GAAP net cash burn is presented in the accompanying slides. 2 PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p3g1.jpg)

MRI is the Clinical Gold Standard, But Capacity and Access Are Limited The MRI You Know The MRI You Wish For Significantly less expensive, no High-cost and complex site shielding or siting required. requirements limit access Available at any healthcare facility Need for highly trained No dedicated personnel to operate. personnel constrains capacity Easy to learn how to scan Limited availability leads to Imaging available to support triage delayed diagnosis and care and point of care decision making and safe to scan "anywhere" Inpatient transport increases No patient transport; significant risk of adverse events cost and personnel efficiencies for critical care patients 3 PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p4g1.jpg)

Large Market Potential Bringing MRI to Multiple Sites of Care 1 Sizeable and Growing US TAM Through New Sites of Care $1.5B $6B+ $16B+ Outpatient Settings Community Settings Inpatient Settings 2025+ 2026+ 2023+ 2 Emergency departments Urgent care facilities Adult critical care 4,000+ 10,000+ Neurology clinics 25,000+ Nursing homes Peds critical care Infusion centers Concierge medicine 1) TAM Calculation Based on Number of Sites of Care (Company Estimates on File) Multiplied by US Device ASP 4 PROPERTY OF HYPERFINE.©2026. All rights reserved. 2) Data as of 2020

------

![](g949104ex99_2p5g1.jpg)

The Swoop System Transforms and Expands the Reach of Brain Imaging Diagnostic Images Captured in Portable, Compact Design Goes Simplified Set Up and Scanning for Directly to the Patient Broad Usability Multiple Sites of Care USING THE SWOOP SYSTEM IMPROVES MRI CAPACITY AND ACCESS WITH MEANINGFUL CLINICAL AND ECONOMIC BENEFIT FOR PATIENTS, CLINICIANS AND PROVIDERS 5 PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p6g1.jpg)

------

![](g949104ex99_2p7g1.jpg)

------

![](g949104ex99_2p8g1.jpg)

FLAIR (Swoop System) FLAIR (High-field 3T) Image Quality of Next Gen Swoop System to Drive Broad Adoption Image Quality Approaching Conventional MRI Case Study of Swoop System vs. High-Field 3T 63-year-old female with history of prior infarct presenting with new-onset headache. Physicians performed office-based imaging with the Swoop system, demonstrating chronic infarct without evidence of acute ischemia. Ø Old Infarct Sources: Images from NEURO-PMR study (Case 040) 8 PROPERTY OF HYPERFINE.©2026. All rights reserved. T1 (Gray/White) (Swoop System) T 1 (High-field 3T)

------

![](g949104ex99_2p9g1.jpg)

AI-Enabled Imaging Software Advanced, AI-driven image reconstruction to ultra-low field MRI—unlocking clearer images at lower field strengths Reduces noise and blur with deep learning, enhances image clarity and consistency, provides sharper anatomical detail to support confident diagnoses at the point of care 11 Generations of AI-enabled software A leader in FDA cleared AI-enabled devices POWERING THE FUTURE . OF PORTABLE MRI Source: U.S. FDA Artificial Available on all Swoop systems Intelligence-Enabled Medical Devices List (July 10, 2025) 9 PROPERTY OF HYPERFINE.©2026. All rights reserved. .

------

![](g949104ex99_2p10g1.jpg)

Robust Commercial Growth Strategy Driven By Growth in 3 Business Verticals Hospital Business Office Business International Business • Increase access to MRI • Increase revenue & lower cost • New revenue stream • Make MRI available where • Improve patient progress • Improve access to imaging Value resources are limited • Improve staff and infrastructure • Diagnose with confidence • Support rural and remote utilization • Monitor treatment safely Proposition healthcare • Avoid long wait times • Track disease progression • Reduce transportation wait times • Care patients prefer • ROI assessments • ROI assessments • Leverage hospital studies Clinical & • ACTION PMR • NEURO PMR • Numerous investigator sponsored Economic Data • PRIME (Enrolling) studies • PRISM PMR (Enrolling) • Critical care- adult & pediatric • Neurology practices • Similar hospital sites of care rd Opportunity • Emergency departments • Operating through 3 parties • Hospital clinics • Canada & Europe market access 1 • Operating rooms • India 10 PROPERTY OF HYPERFINE.©2026. All rights reserved. 1) CDCSO approval in December 2025

------

![](g949104ex99_2p11g1.jpg)

Hospital Business • Compelling clinical utility in critical care, emergency triage, neurosurgery and neuro follow up in adults and peds • Strong economic value proposition o Swoop system scans qualify for existing reimbursement (CPT 70551) o Opportunity to increase revenue, cost savings and optimized patient care o Published Peer Reviewed Health Economic Paper Q4'25 o 1–1.5-year breakeven versus 3–4 years for typical capital equipment • Potential for multiple systems within same hospital o ICUs o Emergency department o Hospital-based clinics • Sales Cycle can be quicker in same Health Systems / IDN hospitals o ~60–70% of US hospitals part of Health Systems / IDNs 11 PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p12g1.jpg)

Office Business • A typical neurologist orders 500–600 MRIs 1,2 annually for neurologic conditions such as headaches, dementia, tumor, MS, surgery follow-up • 90% of private neurology practices don't have on- 3 site MR imaging • Affordable and appealing, plug-and-play Swoop system o No specialized siting required o No helium or electrical infrastructure required 4 o No MRI technologist required • Strong economic value proposition o Swoop system scans qualify for existing reimbursement (CPT 70551) o IAC Accreditation enables medical offices to qualify for CMS reimbursement o Opportunity to add incremental revenue stream & improve patient experience 1) https://practicalneurology.com/diseases-diagnoses/imaging-testing/viewpoints-why-neuroimaging-plays- a-critical-role-in-shaping-the-future-of-neurology/30403/ 2) Source: Mindfrog market research (data on file) • Office has shorter sales cycle and fewer decision- 3) The practice of neuroimaging within a neurology office setting, 2013 American Academy of Neurology 4) IAC Standards and Guidelines for MRI Accreditation. State regulations vary. makers than hospital business PROPERTY OF HYPERFINE.©2026. All rights reserved. 12 PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p13g1.jpg)

International Business • Compelling clinical utility transferable globally • Selling primarily into the hospital setting, demonstrated value proposition in remote settings • Optive AI software launch in 10 European languages in Q4'25 • Next generation Swoop system clearance expected in Europe and Canada markets by the end of 2026 • Swoop system referenced in France's largest public 1 hospital procurement body to facilitate nationwide purchases of portable MRI technology • India CDCSO approval in December 2025 • Network of reference sites and key opinion leaders globally through Gates Foundation partnership 13 PROPERTY OF HYPERFINE.©2026. All rights reserved. 1) https://www.uniha.org/qui-sommes-nous/uniha-union-hopitaux-achats

------

![](g949104ex99_2p14g1.jpg)

Scalable Commercialization with US Direct Sales and Global Distribution Network INSTALLED BASE 1 Over 200 Swoop Systems Globally DIRECT DISTRIBUTORS Dedicated Selling & Implementation Teams (~15 FTE in Total) 10+ Markets (2 FTE in Total) Healthy US Pricing & Recurring Revenue Swoop System Manufactured in U.S. Swoop System MSRP (Hospital CAPEX) by Global Contract Manufacturer Partner 14 PROPERTY OF HYPERFINE.©2026. All rights reserved. 1) Installed base includes commercial and research units as of December 2025.

------

![](g949104ex99_2p15g1.jpg)

Multiples Proof Points and Strong Commercial Outlook from Next Gen Swoop System Since Next Gen System Launch Commercial Outlook o US Hospital Pipeline Converted to Next Gen o Overwhelmingly Positive Feedback on System Image Quality and Radiology Community Ready to Support, Read, and Endorse o Majority of US Sales with Next Gen Swoop System o Inbound Requests for Quotes, ROI Evaluation, Product Demos, and Image o Realizing Increased Pricing with Next Gen Reviews System sales o Robust Pipeline of "Multiple" Deals o Next Gen System Hospital Placements § In Adult Critical Care o Actively Engaged with Several IDNs to Standardized Care § In Pediatric Critical Care o Inbound Interests For Use Case Expansion § In Hospital Emergency Department (e.g. Neurosurgery, Micro Hospitals) § Multi-System Placement in a Single Account in Single Quarter o NeuroNet Partnership Supporting Office Adoption; Office Pipeline Strengthening o Office Commercial Activity Focused on Lead Generation o Product Segmentation Strategically Used To Optimize Office Setting Pricing § 1st Next Gen System Placement in Initial Quarter of Launch o Recent International Launch of Optive AI § Reimbursement Validated in Office Pilot Software Q4'25. Next Gen System expected o Next Gen System Manufacturing Ramp before Q4'26 Tracking Market Demand 15 PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p16g1.jpg)

1 2025 Preliminary Financial Profile Strong Revenue and Cash Burn Performance. Substantial Sequential Improvement 2 REVENUE CASH BURN $5.3 $10.1 -19% +54% $8.1 -27% $3.4 +27% $5.9 -3% $5.7 $2.7 +26% $2.1 1 1 Q1'25 Q2'25 Q3'25 Q4'25 Est. Q1'25 Q2'25 Q3'25 Q4'25 Est. 1) Preliminary, Unaudited Financial Results of Q4'25 The unaudited, preliminary Q4 2025 financial results presented above for Q4 2025 Revenue and Cash Burn are based on current expectations and may be adjusted as a result of, among other things, completion of quarterly procedures. This financial information does not represent a comprehensive statement of the Company's financial results for Q4 2025 and remains subject to the completion of financial closing procedures and internal reviews. 16 PROPERTY OF HYPERFINE.©2026. All rights reserved. 2) Cash burn is calculated as change in cash and cash equivalents less net financing proceeds, which includes shares issued under the Company's "at-the-market" offering program, the Company's February 2025 registered direct offering, and the Company's October 2025 underwritten public offering. Cash and cash equivalents were $37.6 million as of December 31, 2024, $33.1 million as March 31, 2025, $25.4 million as of June 30, 2025, $21.6 million as of September 30, 2025, and preliminary, unaudited are expected to be approximately $35.1 million as of December 31, 2025; net financing proceeds in the aggregate were $5.5 million for the quarter ended March 31, 2025, $0.5 million for the quarter ended June 30, 2025, $2.0 million for the quarter ended September 30, 2025, and preliminary, unaudited are expected to be approximately $19.3 million for the quarter ended December 31, 2025. All quarterly numbers presented herein are unaudited.

------

![](g949104ex99_2p17g1.jpg)

Solid Financial Fundamentals "Tale of 2 Halves" Revenue and Realizing Operating Leverage Key Takeaways 2 REVENUE AND GROSS MARGIN CASH BURN • Transition to Commercial Stage 2023 2024 2025 Est. Organization in 2025 0.52 45 Q3'25 YTD 49.1% $42.3 • Next Generation Swoop System Gross Margin % 16 Launched Mid'25 40 45.7% $38.4 0.47 1 14 $13.5 43.1% • Office Market Launched Mid '25 $12.9 35 Gross Margin (%) 0.42 1 12 • New Technology, US Site of Care $29.9 $11.0 30 Expansion and International Drive 1 1 2H'25 2H'25 Revenue Growth 10 0.37 25 $8.7 $11.7 • Volume, Pricing and Efficient 8 20 Manufacturing Operations Drive 0.32 GM% Expansion Revenue 6 15 • Lean Organization Focused on 0.27 1H'25 Commercial Execution Drives Cash 4 10 1H'25 $18.2 Burn Reductions w/ Scaling Revenue 0.22 $4.8 2 5 • $35.1M of Cash and Cash Equivalents 1 as of 12/31/25 0 0.17 0 1 1 2023 2024 2025 Est. 2023 2024 2025 Est. • Expected to Provide Cash Runway Into 2H'27 1) Preliminary, Unaudited Financial Results of FY25. The unaudited, preliminary FY25 financial results presented above for 2025 Revenue, Cash and Cash Burn are based on current expectations and may be adjusted as a result of, among other things, completion of quarterly and annual audit procedures. This financial information does not represent a comprehensive statement of the Company's financial results for 2025 and remains subject to the completion of financial closing procedures and internal reviews. 17 PROPERTY OF HYPERFINE.©2026. All rights reserved. 2) Cash burn is calculated as change in cash and cash equivalents less net financing proceeds, which includes shares issued under the Company's "at-the-market" offering program, the Company's February 2025 registered direct offering, and the Company's October 2025 underwritten public offering. Cash and cash equivalents were $117.5 million as of December 31, 2022, $75.2 million as of December 31, 2023, $37.6 million as of December 31, 2024, and preliminary, unaudited are expected to be approximately $35.1 million as of December 31, 2025; there were no financing proceeds for the year ended December 31, 2023 and net financing proceeds in the aggregate were $0.8 million for the year ended December 31, 2024, and preliminary, unaudited are expected to be approximately $27.3 million for the year ended December 31, 2025.

------

![](g949104ex99_2p18g1.jpg)

FUTURE OPPORTUNITIES IN NEW ANATOMIES, INTERVENTIONS AND CAPABILITIES HYPERFINE PATENTS AND KNOW-HOW ARE WELL POSITIONED TO DELIVER IN MULTIPLE MARKETS WITH ADDITIONAL GROWTH AND VALUE-ADDED SERVICES Future Next Now Mobile for acute care Mobile brain health Expanded sequence Neuro and private practice offering Expansion Screening services Intraoperative use Contrast agents C-spine Neonatal imaging Platform Diabetic foot expansion: Anatomy and Interventions System accessories Breast Applications platform AI-powered clinical App marketplace Teleradiology integration decision support SaaS Software and Data exchange PULSE Services Open developer platform (Developer subscription) ecosystem 18 PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p19g1.jpg)

Leadership Team With Proven Track Record of Success Maria Brett Hale Tom Rob Chief Administrative Fasciano, PhD Sainz Teisseyre, PhD Officer and Chief President and Chief Chief Operating Chief Regulatory Financial Officer Executive Officer Officer and Quality Officer Edmond Rafael Donnay Chi Nguyen Todd Finch Senior Vice Senior Vice President Vice President Knopp, MD President of of Office and of US Sales Chief Medical Hospital Business Community Business Officer Eric Rafael Willis O'Halloran, PhD Vice President of Vice President of International Technology 19 PROPERTY OF HYPERFINE.©2026. All rights reserved.

------

![](g949104ex99_2p20g1.jpg)

------

![](g949104ex99_2p21g1.jpg)